Invivoscribe's Products and Services
Invivoscribe offers LymphoTrack Assay* kits to provide a streamlined solution for Next Generation Sequencing (NGS) detection of clonality, somatic hypermutation (SHM) and minimal residual disease (MRD) using Illumina and ThermoFisher platforms. These assays allow cost-effective multiplexing of up to 7 targets tested in-house. The intuitive MRD bioinformatics software includes a Project Planner to achieve the desired level of sensitivity and confidence, and facilitates simultaneous tracking of up to 5 B- or T-cell gene rearrangements to a sensitivity of 10-6. Our LymphoTrack Assays*, LymphoQuant Internal Controls*, Low Positive Controls*, and intuitive bioinformatics software*, enables researchers to accurately identify and trend disease with unprecedented simplicity. The LeukoStrat CDx FLT3 Mutation Assay** is approved by the FDA, MHLW, ARTG, and is also CE-marked. It is the only CDx approved assay for all FLT3 tyrosine kinase inhibitors, detecting both FLT3 ITD and TKD driver mutations. The globally standardized assay includes software that generates mutant/wildtype signal ratios, enabling targeted AML therapeutics. The Invivoscribe wholly owned LabPMM, is a network of global reference laboratories that providing clinical and pharmaceutical communities with worldwide access to standardized molecular clinical testing and CRO services, including comprehensive panels to detect MRD by NGS and Multiparameter Flow Cytometry. Invivoscribe is your ideal partner to accelerate approvals of new drugs and treatments by supporting international clinical trials, custom biomarker assays, and CDx development. *For research use only. Not for use in diagnostic procedures. **For in vitro diagnostic use. For additional information and intended uses please visit us at www.invivoscribe.com or contact us at inquiry@invivoscribe.com...
More Info Less Info